Latest Pharma Insights
MFN Is Reshaping Pharma: More European Launch Delays, Headaches For Mid-Sized Pharma
Adapting to the challenges of Most Favored Nation pricing is a top priority in biopharma boardrooms, though the pricing gulf between the US and other developed nations looks impossible to bridge.
Scrip - August 28, 2026
Adapting to the challenges of Most Favored Nation pricing is a top priority in biopharma boardrooms, though the pricing gulf between the US and other developed nations looks impossible to bridge.
Scrip - August 28, 2026
Diagnosing More, For Less: The Promise Of ‘Near-Perfect’ Long-Read Genomics
Combining long reads with AI, pangenome references and diploid assembly could dramatically improve genetic disease diagnosis, researchers say.
Medtech Insight - August 28, 2026
Combining long reads with AI, pangenome references and diploid assembly could dramatically improve genetic disease diagnosis, researchers say.
Medtech Insight - August 28, 2026
ESC: Cytokinetics Confirms Strong Case For Myqorzo Label Expansion
The firm has revealed the extent of the win seen in the ACACIA-HCM study in patients with symptomatic non-obstructive hypertrophic cardiomyopathy, a setting where Bristol Myers Squibb's rival cardiac myosin inhibitor Camzyos failed.
Scrip - August 28, 2026
The firm has revealed the extent of the win seen in the ACACIA-HCM study in patients with symptomatic non-obstructive hypertrophic cardiomyopathy, a setting where Bristol Myers Squibb's rival cardiac myosin inhibitor Camzyos failed.
Scrip - August 28, 2026
Apotex Addresses Tariffs As US-Canada Tensions Rise
Following the recent threat of US tariffs on imported generics from 2028, Apotex’s management has spoken about the uncertainty that remains surrounding the measure - but at the same time, says it is aligned with the Trump administration on its underlying goals.
Generics Bulletin - August 28, 2026
Following the recent threat of US tariffs on imported generics from 2028, Apotex’s management has spoken about the uncertainty that remains surrounding the measure - but at the same time, says it is aligned with the Trump administration on its underlying goals.
Generics Bulletin - August 28, 2026
Takeda Patent Suit Puts Early Entyvio Biosimilar Launches Under Pressure
Takeda’s six-patent suit against Polpharma puts an early legal test in front of first-wave Entyvio biosimilar entrants, with both Polpharma and Alvotech targeting potential US approval in 2027.
Generics Bulletin - August 28, 2026
Takeda’s six-patent suit against Polpharma puts an early legal test in front of first-wave Entyvio biosimilar entrants, with both Polpharma and Alvotech targeting potential US approval in 2027.
Generics Bulletin - August 28, 2026
Mylan, Lannett Must Face Humana Jury On Generic Price-Fixing Claims
A US federal court has cleared Humana’s overarching conspiracy and multiple drug-specific claims against Mylan and Lannett for trial, setting up a September bellwether in the generic price-fixing multi-district litigation.
Generics Bulletin - August 28, 2026
A US federal court has cleared Humana’s overarching conspiracy and multiple drug-specific claims against Mylan and Lannett for trial, setting up a September bellwether in the generic price-fixing multi-district litigation.
Generics Bulletin - August 28, 2026
Lupin Targets Bigger Global Role For Europe And Emerging Markets
In an exclusive interview, Lupin’s Thierry Volle describes how the firm is looking to roughly double its Europe and emerging markets business over five years, leaning on specialty care, selective biosimilars and complex generics.
Generics Bulletin - August 28, 2026
In an exclusive interview, Lupin’s Thierry Volle describes how the firm is looking to roughly double its Europe and emerging markets business over five years, leaning on specialty care, selective biosimilars and complex generics.
Generics Bulletin - August 28, 2026
Japan Looks Set To Widen Access To OTC Loxoprofen
Japan's health ministry looks set to let registered drug sellers dispense oral loxoprofen, taking Daiichi Sankyo Healthcare's Loxonin S and around 30 rival products out of the strictest tier of the country's OTC system.
HBW Insight - August 28, 2026
Japan's health ministry looks set to let registered drug sellers dispense oral loxoprofen, taking Daiichi Sankyo Healthcare's Loxonin S and around 30 rival products out of the strictest tier of the country's OTC system.
HBW Insight - August 28, 2026
Top Medtech Companies’ H1 Growth Points To Solid FY 2026 Performance
The top 10 global medtech companies averaged revenue growth of 6.1% in the first half of 2026. That was down 2.4 percentage points on the full year 2025 aggregate performance and points to mid-single digit growth for full-year 2026.
In Vivo - August 28, 2026
The top 10 global medtech companies averaged revenue growth of 6.1% in the first half of 2026. That was down 2.4 percentage points on the full year 2025 aggregate performance and points to mid-single digit growth for full-year 2026.
In Vivo - August 28, 2026
Peptide Supply Error Is Latest Blip On US Regulatory Radar For Compounding Pharmacies
Adverse event reports for at least 30 patients come as FDA considers whether to make additional peptides available to compounders and as supplement industry reminds agency that numerous peptides have been used as dietary ingredients for decades.
HBW Insight - August 28, 2026
Adverse event reports for at least 30 patients come as FDA considers whether to make additional peptides available to compounders and as supplement industry reminds agency that numerous peptides have been used as dietary ingredients for decades.
HBW Insight - August 28, 2026
MFN Is Reshaping Pharma: More European Launch Delays, Headaches For Mid-Sized Pharma
Adapting to the challenges of Most Favored Nation pricing is a top priority in biopharma boardrooms, though the pricing gulf between the US and other developed nations looks impossible to bridge.
Scrip - August 28, 2026
Adapting to the challenges of Most Favored Nation pricing is a top priority in biopharma boardrooms, though the pricing gulf between the US and other developed nations looks impossible to bridge.
Scrip - August 28, 2026
ESC: Cytokinetics Confirms Strong Case For Myqorzo Label Expansion
The firm has revealed the extent of the win seen in the ACACIA-HCM study in patients with symptomatic non-obstructive hypertrophic cardiomyopathy, a setting where Bristol Myers Squibb's rival cardiac myosin inhibitor Camzyos failed.
Scrip - August 28, 2026
The firm has revealed the extent of the win seen in the ACACIA-HCM study in patients with symptomatic non-obstructive hypertrophic cardiomyopathy, a setting where Bristol Myers Squibb's rival cardiac myosin inhibitor Camzyos failed.
Scrip - August 28, 2026
Diagnosing More, For Less: The Promise Of ‘Near-Perfect’ Long-Read Genomics
Combining long reads with AI, pangenome references and diploid assembly could dramatically improve genetic disease diagnosis, researchers say.
Medtech Insight - August 28, 2026
Combining long reads with AI, pangenome references and diploid assembly could dramatically improve genetic disease diagnosis, researchers say.
Medtech Insight - August 28, 2026
Japan Looks Set To Widen Access To OTC Loxoprofen
Japan's health ministry looks set to let registered drug sellers dispense oral loxoprofen, taking Daiichi Sankyo Healthcare's Loxonin S and around 30 rival products out of the strictest tier of the country's OTC system.
HBW Insight - August 28, 2026
Japan's health ministry looks set to let registered drug sellers dispense oral loxoprofen, taking Daiichi Sankyo Healthcare's Loxonin S and around 30 rival products out of the strictest tier of the country's OTC system.
HBW Insight - August 28, 2026
Peptide Supply Error Is Latest Blip On US Regulatory Radar For Compounding Pharmacies
Adverse event reports for at least 30 patients come as FDA considers whether to make additional peptides available to compounders and as supplement industry reminds agency that numerous peptides have been used as dietary ingredients for decades.
HBW Insight - August 28, 2026
Adverse event reports for at least 30 patients come as FDA considers whether to make additional peptides available to compounders and as supplement industry reminds agency that numerous peptides have been used as dietary ingredients for decades.
HBW Insight - August 28, 2026
Apotex Addresses Tariffs As US-Canada Tensions Rise
Following the recent threat of US tariffs on imported generics from 2028, Apotex’s management has spoken about the uncertainty that remains surrounding the measure - but at the same time, says it is aligned with the Trump administration on its underlying goals.
Generics Bulletin - August 28, 2026
Following the recent threat of US tariffs on imported generics from 2028, Apotex’s management has spoken about the uncertainty that remains surrounding the measure - but at the same time, says it is aligned with the Trump administration on its underlying goals.
Generics Bulletin - August 28, 2026
Takeda Patent Suit Puts Early Entyvio Biosimilar Launches Under Pressure
Takeda’s six-patent suit against Polpharma puts an early legal test in front of first-wave Entyvio biosimilar entrants, with both Polpharma and Alvotech targeting potential US approval in 2027.
Generics Bulletin - August 28, 2026
Takeda’s six-patent suit against Polpharma puts an early legal test in front of first-wave Entyvio biosimilar entrants, with both Polpharma and Alvotech targeting potential US approval in 2027.
Generics Bulletin - August 28, 2026
Mylan, Lannett Must Face Humana Jury On Generic Price-Fixing Claims
A US federal court has cleared Humana’s overarching conspiracy and multiple drug-specific claims against Mylan and Lannett for trial, setting up a September bellwether in the generic price-fixing multi-district litigation.
Generics Bulletin - August 28, 2026
A US federal court has cleared Humana’s overarching conspiracy and multiple drug-specific claims against Mylan and Lannett for trial, setting up a September bellwether in the generic price-fixing multi-district litigation.
Generics Bulletin - August 28, 2026
Lupin Targets Bigger Global Role For Europe And Emerging Markets
In an exclusive interview, Lupin’s Thierry Volle describes how the firm is looking to roughly double its Europe and emerging markets business over five years, leaning on specialty care, selective biosimilars and complex generics.
Generics Bulletin - August 28, 2026
In an exclusive interview, Lupin’s Thierry Volle describes how the firm is looking to roughly double its Europe and emerging markets business over five years, leaning on specialty care, selective biosimilars and complex generics.
Generics Bulletin - August 28, 2026
Top Medtech Companies’ H1 Growth Points To Solid FY 2026 Performance
The top 10 global medtech companies averaged revenue growth of 6.1% in the first half of 2026. That was down 2.4 percentage points on the full year 2025 aggregate performance and points to mid-single digit growth for full-year 2026.
In Vivo - August 28, 2026
The top 10 global medtech companies averaged revenue growth of 6.1% in the first half of 2026. That was down 2.4 percentage points on the full year 2025 aggregate performance and points to mid-single digit growth for full-year 2026.
In Vivo - August 28, 2026